Reports Q2 revenue $39.5M, consensus $35.58M. “The second quarter marked a significant step forward in Phathom’s journey toward becoming a growth-oriented and profitable GI company,” said CEO Steve Basta. “We delivered strong sequential revenue growth, implemented strategic cost reductions, and shifted our commercial strategy to focus on high-value prescribers. With over 580,000 VOQUEZNA prescriptions filled to date and extended market exclusivity, we believe we are well-positioned to accelerate VOQUEZNA’s adoption and achieve profitability in 2026.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Avidity, Phathom mentioned as potential takeout targets at Needham
- Phathom Pharmaceuticals appoints Anne Marie Cook as CLO, corporate secretary
- Largest borrow rate increases among liquid names
- Phathom Pharmaceuticals Gains FDA Exclusivity for VOQUEZNA
- Phathom Pharmaceuticals announces FDA correction to Orange Book Listing